Protective effect of low molecular weight heparin on experimental colitis: Role of neutrophil recruitment and TNF-α production

Inflammation Research

Volumn 51, Issue 4, 2002, Pages 182-187

  Wan, M X ^a   Liu, Q ^a   Wang, Y ^a   Thorlacius, H ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colitis; Leukocyte; Low molecular weight heparin; TNF

Indexed keywords

DALTEPARIN; DEXTRAN SULFATE; LOW MOLECULAR WEIGHT HEPARIN; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CRYPT CELL; DISEASE ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOCHEZIA; HISTOPATHOLOGY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; WEIGHT REDUCTION;

EID: 0036238823     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000290     Document Type: Article

References (35)

1. Tumor necrosis factor and Crohn's disease
2. Tissue destruction by neutrophils
3. Predictors and the rate of medical failure in severe ulcerative colitis
4. Predicting outcome in severe ulcerative colitis
5. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2)
6. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease
7. Paradoxical response to heparin in 10 patients with ulcerative colitis
8. Treatment of corticosteroid-resistant ulcerative colitis with heparin-a report of 16 cases
9. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease
10. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis
11. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions
12. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1)
13. Suppression by intradermal administration of heparin of eosinophil accumulation but not oedema formation in inflammatory reactions in guinea-pig skin
14. Inhibitory effect of locally administered heparin on leukocyte rolling and chemoattractant-induced firm adhesion in rat mesenteric venules in vivo
15. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism
16. Inhibitory effects of low molecular weight heparin on mediator release by mast cells: Preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation
17. Expression of P-selectin on hepatic endothelia and platelets promoting neutrophil removal by liver macrophages
18. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model
19. Low molecular weight heparin inhibits tumor necrosis factor α-induced leukocyte rolling
20. Clinicopathologic study of dextran sulfate sodium experimental murine colitis
21. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models
22. Effect of heparin on dextran sulfate sodium-induced colitis
23. The effect of heparin on trinitrobenzene sulphonic acid-induced colitis in the rat
24. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice
25. Experimental models of inflammatory bowel disease
26. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation
27. Inhibition of selectin-function and leukocyte rolling protects against dextran sodium sulfate-induced murine colitis
28. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents
29. Critical role of P-selectin-dependent rolling in tumor necrosis factor-α -induced leukocyte adhesion and extravascular recruitment in vivo
30. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease
31. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin
32. Hemostasis and heparin therapy in non-specific ulcerative colitis
33. The use of anticoagulants in combined therapy of non-specific ulcerative colitis
34. IBD: A vascular disorder? The case for heparin therapy
35. Vascular complications of inflammatory bowel disease